Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.46 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700170 | 0.94 | SRD5A2 (0.46) | SRD5A2SRD5A1SHBGAR | |
| SCHEMBL9066308 | 0.91 | SRD5A2 (0.46) | SRD5A2SRD5A1SHBGAR | |
| SCHEMBL9216217 | 0.83 | SRD5A2 (0.52) | SRD5A2SRD5A1SHBGAR | |
| SCHEMBL9216224 | 0.83 | SRD5A2 (0.52) | SRD5A2SRD5A1SHBGAR | |
| SCHEMBL9066316 | 0.82 | SRD5A2 (0.39) | SRD5A2SRD5A1SHBGAR | |
| SCHEMBL6692574 | 0.80 | HSD17B7 (0.53) | SRD5A2SRD5A1 | |
| SCHEMBL6694162 | 0.77 | SRD5A2 (0.49) | SRD5A2SRD5A1SHBGAR | |
| SCHEMBL6694699 | 0.76 | SRD5A2 (0.48) | SRD5A2SRD5A1SHBGAR | |
| SCHEMBL9066006 | 0.76 | SRD5A1 (0.51) | SRD5A2SRD5A1AR | |
| SCHEMBL9066010 | 0.76 | SRD5A1 (0.51) | SRD5A2SRD5A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | ENDORECHERCHE, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1321146-A2 | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use | Endorecherche Inc. (CA) | 2003-06-25 | — | — | EP | disclosed |
| EP-1094798-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | Endorecherche Inc. (CA) | 2001-05-02 | — | — | EP | disclosed |
| WO-1999046279-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | HSD17B11, HSD17B3, HSD17B1 | SRD5A2 8/4885SRD5A1 5/4885SHBG 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.